Journal Article > CommentaryFull Text
Nature. 9 February 2022; Volume 602 (Issue 7896); 207-210.; DOI:10.1038/d41586-022-00324-y
Swaminathan S, Pecoul B, Abdullah H, Christou C, Gray G, et al.
Nature. 9 February 2022; Volume 602 (Issue 7896); 207-210.; DOI:10.1038/d41586-022-00324-y
Journal Article > CommentaryFull Text
PLOS Med. 11 May 2015; Volume 12 (Issue 5); DOI:10.1371/journal.pmed.1001831
Balsegaram M, Brechot C, Farrar J, Heymann D, Ganguly N, et al.
PLOS Med. 11 May 2015; Volume 12 (Issue 5); DOI:10.1371/journal.pmed.1001831
Journal Article > CommentaryFull Text
PLoS Negl Trop Dis. 31 October 2013; Volume 7 (Issue 10); e2300.; DOI:10.1371/journal.pntd.0002300
Hotez PJ, Dumonteil E, Cravioto MB, Bottazzi ME, Tapia-Conyer R, et al.
PLoS Negl Trop Dis. 31 October 2013; Volume 7 (Issue 10); e2300.; DOI:10.1371/journal.pntd.0002300
Journal Article > ResearchFull Text
Lancet Global Health. 1 December 2013 (Issue 6); DOI:10.1016/S2214-109X(13)70078-0
Pedrique B, Strub-Wourgaft N, Some C, Olliaro PL, Trouiller P, et al.
Lancet Global Health. 1 December 2013 (Issue 6); DOI:10.1016/S2214-109X(13)70078-0
In 1975-99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011.
Journal Article > CommentaryFull Text
Science. 10 August 2001; Volume 293 (Issue 5532); 1049-1051.; DOI:10.1126/science.1061861
Gupta RS, Kim JH, Espinal MA, Caudron JM, Pecoul B, et al.
Science. 10 August 2001; Volume 293 (Issue 5532); 1049-1051.; DOI:10.1126/science.1061861
Journal Article > CommentaryFull Text
AIDS. 3 December 2004; Volume 18 (Issue 18); 2353-2360.
Calmy A, Klement E, Teck R, Berman D, Pecoul B, et al.
AIDS. 3 December 2004; Volume 18 (Issue 18); 2353-2360.
Journal Article > LetterAbstract
Nature. 27 April 2014; Volume 507 (Issue 7493); DOI:10.1038/507431d
Pecoul B, Balasegaram M
Nature. 27 April 2014; Volume 507 (Issue 7493); DOI:10.1038/507431d
Journal Article > ResearchFull Text
Southeast Asian J Trop Med Public Health. 1 December 1991
Decludt B, Pecoul B, Biberson P, Lang R, Imivithaya S
Southeast Asian J Trop Med Public Health. 1 December 1991
Right from the arrival of the displaced Karen people in Thailand, Médecins sans Frontières (MSF) identified malaria as the top priority problem. A program of patient care based on the coupled laboratory/dispensary was set up in April 1984. Immediately a system of surveillance of morbidity and mortality from malaria was set up. This study consisted of analysing data gathered over a period of five years. During this time, the displaced population increased from 9,000 to 20,000. Analysis of the trends shows a hyperendemic situation with an annual incidence rate of 1,067 per thousand in 1984. This figure was 600 per thousand in 1988. 1,500 blood smears were checked each month and the positive predictive value of clinical suspicion was 45% on average. Plasmodium falciparum represented 80% of infections. The malaria case fatality ratio over the course of the last two years of surveillance was 0.3%. Five years observation show that the fight against malaria in this region can be based on the development of curative services and laboratories.
Journal Article > ResearchFull Text
Trop Med Int Health. 1 November 2001; Volume 6 (Issue 11); 957-959.; DOI:10.1046/j.1365-3156.2001.00764.x
Etchegorry MG, Helenport J, Pecoul B, Jannin J, Legros D
Trop Med Int Health. 1 November 2001; Volume 6 (Issue 11); 957-959.; DOI:10.1046/j.1365-3156.2001.00764.x
Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance. Availability of HAT drugs is poor and their production in danger because of technical, ecological and economic constraints. In view of this dramatic situation, a network involving experts from NGOs, WHO and pharmaceutical producers was commissioned with updating estimates of need for each HAT drug for the coming years; negotiations with potential producers of new drugs such as eflornithine; securing sustainable manufacturing of existing drugs; clinical research into new combinations of these drugs for first and second-line treatments; centralizing drug purchases and their distribution through a unique non-profit entity; and addressing regulatory and legal issues concerning new drugs.